Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites (Q91173369)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

26 October 2022

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

Kenji Hashimoto

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

author name string

Chun Yang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

Ailin Luo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

publication date

7 November 2019

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

26 October 2022

Translational Psychiatry

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

26 October 2022

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

page(s)

280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution

20 April 2020

copyright license

1 reference

26 October 2022

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Emerging role of glutamate in the pathophysiology of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Targeting glutamate signalling in depression: progress and prospects

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Rapid-Acting Antidepressants

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

An update on ketamine and its two enantiomers as rapid-acting antidepressants

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Antidepressant effects of ketamine in depressed patients

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Administration of ketamine for unipolar and bipolar depression.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine: A Paradigm Shift for Depression Research and Treatment

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Rapid antidepressant effects and abuse liability of ketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Side-effects associated with ketamine use in depression: a systematic review.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Do the dissociative side effects of ketamine mediate its antidepressant effects?

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Taming the ketamine tiger. 1965.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S ( )-ketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine's antidepressant action: beyond NMDA receptor inhibition

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Detrimental Side Effects of Repeated Ketamine Infusions in the Brain.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Glutamate-based antidepressants: 20 years on.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

(R)- and (S)-ketamine induce differential fMRI responses in conscious rats

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

5-Hydroxytryptamine-independent antidepressant actions of (R)-ketamine in a chronic social defeat stress model

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

mTOR Signaling in Growth, Metabolism, and Disease.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Molecular neurobiology of mTOR

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Acute systemic rapamycin induces neurobehavioral alterations in rats

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Essential roles of neuropeptide VGF regulated TrkB/mTOR/BICC1 signaling and phosphorylation of AMPA receptor subunit GluA1 in the rapid antidepressant-like actions of ketamine in mice

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine promotes rapid and transient activation of AMPA receptor-mediated synaptic transmission in the dorsal raphe nucleus

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Effects of ketamine administration on mTOR and reticulum stress signaling pathways in the brain after the infusion of rapamycin into prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Monitoring Ketamine Treatment Response in a Depressed Patient via Peripheral Mammalian Target of Rapamycin Activation

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Neurobiology of depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Critical role of brain-derived neurotrophic factor in mood disorders

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

A neurotrophic model for stress-related mood disorders

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

BDNF - a key transducer of antidepressant effects.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

PGC-1α-FNDC5-BDNF signaling pathway in skeletal muscle confers resilience to stress in mice subjected to chronic social defeat

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine-induced regulation of TrkB-GSK3β signaling is accompanied by slow EEG oscillations and sedation but is independent of hydroxynorketamine metabolites

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Synaptic dysfunction in depression: potential therapeutic targets

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Spine synapse remodeling in the pathophysiology and treatment of depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

(R)-Ketamine Rapidly Ameliorates the Decreased Spine Density in the Medial Prefrontal Cortex and Hippocampus of Susceptible Mice After Chronic Social Defeat Stress

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

S-Ketamine Reverses Hippocampal Dendritic Spine Deficits in Flinders Sensitive Line Rats Within 1 h of Administration

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine: its mechanism(s) of action and unusual clinical uses.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Lack of Opioid System in the Antidepressant Actions of Ketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Effects of a ketamine metabolite on synaptic NMDAR function.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation Model

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Now is the time for (2R,6R)-hydroxynorketamine to be viewed independently from its parent drug

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Is (S)-norketamine an alternative antidepressant for esketamine?

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Disruptive Psychopharmacology

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

What Are the Causes for Discrepancies of Antidepressant Actions of (2R,6R)-Hydroxynorketamine?

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

The critical importance of basic animal research for neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1038/S41398-019-0624-1

7 January 2021

10.1038/S41398-019-0624-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31699965 AND SRC:MED&resulttype=core&format=json

20 April 2020

PubMed publication ID

31699965

1 reference